Patent · US Active

Use of the cathelicidin LL-37 and derivatives thereof for wound healing

US8936807B2 · kind B2 · utility

4Cited by

4References

2Claims

0Family size

Assignee

Lipopeptide AB · SE

Inventors

Mona Ståhle-Bäckdahl · Stockholm, SE
Johan Heilborn · Stockholm, SE
Anders Carlsson · Lund, SE
Conny Bogentoft · Nordstraße, SE

Key dates

Filing date	Jul 9, 2013
Grant date	Jan 20, 2015
Priority date	—
Expiry date	Jul 9, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2500/36
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.